RA cohort: Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)
OA cohort: Diagnosis of osteoarthritis made by physician.

NCT02874092_inc_T1
Condition
RA
NCT02874092_inc_T2
Drug
MTX
NCT02874092_inc_T3
Multiplier
stable doses
NCT02874092_inc_T4
Multiplier
10 to 25 mg weekly
NCT02874092_inc_T5
Temporal
for at least 12 weeks
NCT02874092_inc_T6
Measurement
DAS28
NCT02874092_inc_T7
Value
3.2 or higher
NCT02874092_inc_T9
Condition
OA
NCT02874092_inc_T10
Condition
osteoarthritis
NCT02874092_inc_T11
Observation
made by physician
NCT02874092_inc_T12
Scope
MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)
NCT02874092_inc_T13
Scope
osteoarthritis made by physician